NewslettersCell Therapy NewsHuman Immunology News Off-The-Shelf Third-Party HSC-Engineered iNKT Cells for Ameliorating GvHD While Preserving GvL Effect in the Treatment of Blood Cancers By Danielle Corrigan - August 8, 2022 0 Scientists reported the successful generation of third-party hematopoietic stem cell (HSC)-engineered human invariant natural killer T (iNKT) cells, using a method combining HSC gene engineering and in vitro HSC differentiation. [iScience] AbstractFull ArticleGraphical Abstract